CooperVision and CooperSurgical, subsidiaries of CooperCompanies, reported another successful quarter with record revenues and earnings. Revenue increased 11% in Q4, with key performances in daily silicone hydrogel and myopia management lenses, propelling a 19% growth. The MyDay multifocal launch has received positive feedback, contributing to share gains. For the full year, revenues and free cash flow were record-breaking. As Cooper enters fiscal 2022, it anticipates continued growth with revenue projections of $3.032 billion to $3.090 billion and non-GAAP earnings per share between $13.60 and $14.00, representing 6-8% and 9.5-12.5% growth, respectively. The pending acquisition of Generate Life Sciences is expected to further enhance the company's position in fertility and labor and delivery, with an estimated $0.50 non-GAAP earnings per share accretion in year one.